Navigation Links
Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009
Date:9/8/2009

LAIYANG, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (the "Company", "Jiangbo"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today reaffirmed its previously announced guidance for fiscal year 2009. The Company expects to meet or exceed its goals of $111 to $116 million in revenue and operating income of $40 to $43 million for the fiscal year ending June 30, 2009.

"We plan to report our annual results for the fiscal year 2009 by the end of this month and are pleased to reaffirm we are on track to achieve our financial goals," said Mr. Wubo Cao, Chief Executive Officer of Jiangbo. "We continue to revamp the production lines which we acquired from Hongrui earlier this year. We expect this project to be completed in May 2010, when we should be able to begin mass production of other profitable TCM products. Thus, we continue to feel confident in maintaining a healthy growth rate over the long term."

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of fu
'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
2. Onyx Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
5. Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting
6. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
7. NovaBay(R) Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference September 10, 2009 in New York City
8. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
9. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
10. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
11. Onyx Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... BOSTON , March 26, 2015 /PRNewswire/ ... ), a global clinical research organization ... signed a definitive agreement to acquire all ... India ("QSI"), a leading provider of specialized ... refers to the collection, detection, assessment, monitoring, ...
(Date:3/25/2015)... pharmaceutical market is one of the most attractive in ... size, plus a growing economy and increasing government investment ... International. The Russian market is set to grow at ... growth estimates around 10-15% annually reaching an approximate market ... Green Cross Green Cross provides total healthcare ...
(Date:3/25/2015)... NEW YORK , March 25, 2015 /PRNewswire/ ... has commenced Factual Stock Report coverage on ... Bioceuticals (OTCQX: ATTBF; CSE: ATT): is a specialty ... subsidiaries of cultivating, licensing and marketing proprietary ingredients, ... medicinal markets in North America ...
(Date:3/25/2015)... Fla. , March 25, 2015  Point-of-Care ... and management consulting firm, has launched the ePrescribing ... to simplify tracking of ePrescribing regulatory requirements in ... "The ePrescribing regulatory landscape continues to change rapidly, ... deliver what the industry, and ultimately patients, need," ...
Breaking Biology Technology:PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Point-of-Care Partners Launches the ePrescribing State Law Capsule 2
... March 23, 2011 Tengion, Inc. (Nasdaq: ... the addition of two renal research and clinical experts, ... from the Harvard Stem Cell Institute and ... & Development Advisors. This panel provides counsel to Tengion ...
... nanotubes dipped in a polymer solution equal the energy output ... of Case Western Reserve University engineers has found. The ... power output and maintain the other advantages by matching the ... they,ve proved the simple technique can knock down one of ...
... Spherix Incorporated (Nasdaq: SPEX), ... diabetes, metabolic syndrome and atherosclerosis; and providers of ... biotechnology and pharmaceutical companies, today announced that its ... the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference to be ...
Cached Biology Technology:Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 2Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 3Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 4Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 5Cheap catalyst made easy 2Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference 2Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference 3
(Date:3/23/2015)... NEW YORK , March 23, 2015   ... digital property management company, today announced that the Company ... platform for both enterprise and consumers at Connect:ID on ... D.C. HOYOS Labs will highlight the IEEE ... 1U TM ; and enterprise access control system. ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report to ... for Iris Biometrics in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Latin America . ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... biomedical and health informatics, sent comments to the federal ... (DHHS/ ONCHIT), which has actively supported and incentivized the ... over the last year, and which solicited comment, through ... support for achieving meaningful use of EHRs in 2013 ...
... A new non-surgical post-mortem technique that has the ... the world has been pioneered by forensic pathologists and ... the University Hospitals of Leicester NHS Trust. The ... Forensic Pathology Unit, at the University of Leicester, has ...
... how farmers could protect themselves by growing a greater ... BioScience , has highlighted economical steps that farmers ... global climate change, including a greater frequency of extreme ... a policy priority for agriculture. The survey, by Brenda ...
Cached Biology News:AMIA on meaningful use: Invest in people and technology 2New non-surgical autopsy technique set to revolutionize post-mortem practice 2
... Concentrated x 10 This pH 9.9 ... prior to immunohistochemical staining procedures. It is ... mounted on glass slides. For particular antigens, ... especially effective. It should be noted that ...
... 9 (x 10) This product is ... heat-induced target retrieval prior to immunohistochemical staining ... formalin-fixed, paraffin-embedded tissue sections mounted on glass ... pH 6, the use of Target Retrieval ...
... Maximizer kit, 110 to 220 V, ... and doubles flow rates and valve ... The kit includes the Maximizer base ... kit, tubing kit, system cable 30, ...
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
Biology Products: